Indaptus Therapeutics (INDP) Competitors

$1.22 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.18 -0.04 (-3.28%)

As of 05/22/2026 07:59 PM Eastern

INDP vs. LIAN, MDCX, HOTH, BLRX, and KPRX

Should you buy Indaptus Therapeutics stock or one of its competitors? MarketBeat compares Indaptus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Indaptus Therapeutics include LianBio (LIAN), Medicus Pharma (MDCX), Hoth Therapeutics (HOTH), BioLineRx (BLRX), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical products" industry.

How does Indaptus Therapeutics compare to LianBio?

LianBio (NASDAQ:LIAN) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

In the previous week, LianBio's average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
Indaptus Therapeutics	Neutral

74.8% of LianBio shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 7.6% of LianBio shares are held by insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

LianBio's return on equity of -33.17% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

LianBio is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

Summary

Indaptus Therapeutics beats LianBio on 5 of the 9 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Medicus Pharma?

Indaptus Therapeutics (NASDAQ:INDP) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Medicus Pharma has a consensus target price of $9.00, suggesting a potential upside of 2,900.00%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Medicus Pharma had 10 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 10 mentions for Medicus Pharma and 0 mentions for Indaptus Therapeutics. Medicus Pharma's average media sentiment score of 1.09 beat Indaptus Therapeutics' score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Indaptus Therapeutics	Neutral
Medicus Pharma	Positive

Medicus Pharma is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Indaptus Therapeutics' return on equity of -1,030.07% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
Medicus Pharma	N/A	-3,137.84%	-311.33%

7.1% of Indaptus Therapeutics shares are owned by institutional investors. 23.6% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Indaptus Therapeutics has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of -0.47, indicating that its stock price is 147% less volatile than the broader market.

Summary

Indaptus Therapeutics beats Medicus Pharma on 7 of the 13 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Hoth Therapeutics?

Hoth Therapeutics (NASDAQ:HOTH) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

In the previous week, Hoth Therapeutics had 3 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 3 mentions for Hoth Therapeutics and 0 mentions for Indaptus Therapeutics. Hoth Therapeutics' average media sentiment score of 0.57 beat Indaptus Therapeutics' score of 0.00 indicating that Hoth Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Hoth Therapeutics	Positive
Indaptus Therapeutics	Neutral

Hoth Therapeutics' return on equity of -165.25% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hoth Therapeutics	N/A	-165.25%	-143.61%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

7.1% of Hoth Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 6.9% of Hoth Therapeutics shares are held by company insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Hoth Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hoth Therapeutics	N/A	N/A	-$12.47M	-$0.80	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

Hoth Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

Hoth Therapeutics presently has a consensus target price of $5.00, indicating a potential upside of 624.64%. Given Hoth Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Hoth Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hoth Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Hoth Therapeutics beats Indaptus Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Indaptus Therapeutics compare to BioLineRx?

Indaptus Therapeutics (NASDAQ:INDP) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Indaptus Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -99.58%. BioLineRx's return on equity of -5.61% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
BioLineRx	-99.58%	-5.61%	-2.81%

BioLineRx has higher revenue and earnings than Indaptus Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
BioLineRx	$1.18M	11.28	-$1.17M	-$0.17	N/A

7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 23.6% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Indaptus Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, BioLineRx has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

In the previous week, BioLineRx had 3 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 3 mentions for BioLineRx and 0 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.00 equaled BioLineRx'saverage media sentiment score.

Company	Overall Sentiment
Indaptus Therapeutics	Neutral
BioLineRx	Neutral

Summary

BioLineRx beats Indaptus Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Kiora Pharmaceuticals?

Indaptus Therapeutics (NASDAQ:INDP) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Kiora Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 290.63%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Indaptus Therapeutics' average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Indaptus Therapeutics	Neutral
Kiora Pharmaceuticals	Neutral

Indaptus Therapeutics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.48, suggesting that its stock price is 148% less volatile than the broader market.

Kiora Pharmaceuticals' return on equity of -59.30% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Kiora Pharmaceuticals has higher revenue and earnings than Indaptus Therapeutics. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Kiora Pharmaceuticals	$16.02M	0.71	-$10.84M	-$2.71	N/A

7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 23.6% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Kiora Pharmaceuticals beats Indaptus Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Indaptus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDP vs. The Competition

Export

Metric	Indaptus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$138.16M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-0.08	17.79	21.22	25.66
Price / Sales	N/A	336.21	562.28	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	122.00	5.86	10.31	7.14
Net Income	-$20.85M	$74.99M	$3.57B	$335.98M
7 Day Performance	-8.27%	3.11%	6.43%	4.15%
1 Month Performance	-63.03%	-3.05%	3.57%	2.54%
1 Year Performance	-88.19%	34.38%	34.07%	35.06%

Indaptus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDP Indaptus Therapeutics	0.3288 of 5 stars	$1.22 flat	N/A	-88.2%	$138.16M	N/A	N/A	6	Gap Down High Trading Volume
LIAN LianBio	N/A	$0.11 flat	N/A	-69.4%	$11.90M	N/A	N/A	110
MDCX Medicus Pharma	3.2732 of 5 stars	$0.29 +4.3%	$9.00 +3,003.4%	-95.9%	$11.62M	N/A	N/A	N/A	Positive News Analyst Revision Gap Down
HOTH Hoth Therapeutics	2.7684 of 5 stars	$0.60 0.0%	$5.00 +733.5%	-19.2%	$11.48M	N/A	N/A	4	Gap Down
BLRX BioLineRx	0.6982 of 5 stars	$2.75 +4.6%	N/A	-16.4%	$11.44M	$1.18M	N/A	40	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDP) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indaptus Therapeutics (INDP) Competitors

INDP vs. LIAN, MDCX, HOTH, BLRX, and KPRX

How does Indaptus Therapeutics compare to LianBio?

Summary

How does Indaptus Therapeutics compare to Medicus Pharma?

Summary

How does Indaptus Therapeutics compare to Hoth Therapeutics?

Summary

How does Indaptus Therapeutics compare to BioLineRx?

Summary

How does Indaptus Therapeutics compare to Kiora Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indaptus Therapeutics (INDP) Competitors

INDP vs. LIAN, MDCX, HOTH, BLRX, and KPRX

How does Indaptus Therapeutics compare to LianBio?

Does the media prefer LIAN or INDP?

Do insiders & institutionals have more ownership in LIAN or INDP?

Is LIAN or INDP more profitable?

Which has higher valuation & earnings, LIAN or INDP?

Do analysts rate LIAN or INDP?

Which has more volatility and risk, LIAN or INDP?

Summary

How does Indaptus Therapeutics compare to Medicus Pharma?

Do analysts rate INDP or MDCX?

Does the media refer more to INDP or MDCX?

Which has higher earnings & valuation, INDP or MDCX?

Is INDP or MDCX more profitable?

Do insiders and institutionals have more ownership in INDP or MDCX?

Which has more volatility & risk, INDP or MDCX?

Summary

How does Indaptus Therapeutics compare to Hoth Therapeutics?

Does the media favor HOTH or INDP?

Is HOTH or INDP more profitable?

Do insiders & institutionals have more ownership in HOTH or INDP?

Which has higher earnings & valuation, HOTH or INDP?

Which has more volatility and risk, HOTH or INDP?

Do analysts recommend HOTH or INDP?

Summary

How does Indaptus Therapeutics compare to BioLineRx?

Do analysts recommend INDP or BLRX?

Is INDP or BLRX more profitable?

Which has better earnings and valuation, INDP or BLRX?

Do institutionals and insiders have more ownership in INDP or BLRX?

Which has more risk & volatility, INDP or BLRX?

Does the media prefer INDP or BLRX?

Summary

How does Indaptus Therapeutics compare to Kiora Pharmaceuticals?

Do analysts prefer INDP or KPRX?

Does the media refer more to INDP or KPRX?

Which has more volatility and risk, INDP or KPRX?

Is INDP or KPRX more profitable?

Which has better valuation & earnings, INDP or KPRX?

Do institutionals & insiders have more ownership in INDP or KPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools